491 related articles for article (PubMed ID: 34448958)
1. Immunotherapy for Non-melanoma Skin Cancer.
Shalhout SZ; Emerick KS; Kaufman HL; Miller DM
Curr Oncol Rep; 2021 Aug; 23(11):125. PubMed ID: 34448958
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy for Nonmelanoma Skin Cancer: Facts and Hopes.
Shalhout SZ; Kaufman HL; Emerick KS; Miller DM
Clin Cancer Res; 2022 Jun; 28(11):2211-2220. PubMed ID: 35121622
[TBL] [Abstract][Full Text] [Related]
3. Recent Therapeutic Advances and Change in Treatment Paradigm of Patients with Merkel Cell Carcinoma.
Garcia-Carbonero R; Marquez-Rodas I; de la Cruz-Merino L; Martinez-Trufero J; Cabrera MA; Piulats JM; Capdevila J; Grande E; Martin-Algarra S; Berrocal A
Oncologist; 2019 Oct; 24(10):1375-1383. PubMed ID: 30962295
[TBL] [Abstract][Full Text] [Related]
4. Immunologic Characteristics of Nonmelanoma Skin Cancers: Implications for Immunotherapy.
Hall ET; Fernandez-Lopez E; Silk AW; Dummer R; Bhatia S
Am Soc Clin Oncol Educ Book; 2020 Mar; 40():1-10. PubMed ID: 32207669
[TBL] [Abstract][Full Text] [Related]
5. Immune Checkpoint Inhibitors and Beyond: An Overview of Immune-Based Therapies in Merkel Cell Carcinoma.
Samimi M
Am J Clin Dermatol; 2019 Jun; 20(3):391-407. PubMed ID: 30784027
[TBL] [Abstract][Full Text] [Related]
6. Update in the treatment of non-melanoma skin cancers: the use of PD-1 inhibitors in basal cell carcinoma and cutaneous squamous-cell carcinoma.
Ascierto PA; Schadendorf D
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36455990
[TBL] [Abstract][Full Text] [Related]
7. Surgery in the Era of Immunotherapy for Advanced Head and Neck Non-melanoma Skin Cancer.
Lin A; Schmalbach CE
Curr Oncol Rep; 2023 Jul; 25(7):735-742. PubMed ID: 37010785
[TBL] [Abstract][Full Text] [Related]
8. Immune checkpoint inhibitors to treat cutaneous malignancies.
Barrios DM; Do MH; Phillips GS; Postow MA; Akaike T; Nghiem P; Lacouture ME
J Am Acad Dermatol; 2020 Nov; 83(5):1239-1253. PubMed ID: 32461079
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy for Merkel Cell Carcinoma.
Nagase K; Narisawa Y
Curr Treat Options Oncol; 2018 Sep; 19(11):57. PubMed ID: 30238195
[TBL] [Abstract][Full Text] [Related]
10. Immune Checkpoint Inhibition in Non-Melanoma Skin Cancer: A Review of Current Evidence.
Stonesifer CJ; Djavid AR; Grimes JM; Khaleel AE; Soliman YS; Maisel-Campbell A; Garcia-Saleem TJ; Geskin LJ; Carvajal RD
Front Oncol; 2021; 11():734354. PubMed ID: 34988009
[TBL] [Abstract][Full Text] [Related]
11. The Landmark Series: Non-melanoma Skin Cancers.
Lee AY; Berman RS
Ann Surg Oncol; 2020 Jan; 27(1):22-27. PubMed ID: 31549317
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant Therapy for Non-melanoma Skin Cancer: Updated Therapeutic Approaches for Basal, Squamous, and Merkel Cell Carcinoma.
Zelin E; Zalaudek I; Agozzino M; Dianzani C; Dri A; Di Meo N; Giuffrida R; Marangi GF; Neagu N; Persichetti P; Toffoli L; Conforti C
Curr Treat Options Oncol; 2021 Mar; 22(4):35. PubMed ID: 33725197
[TBL] [Abstract][Full Text] [Related]
13. The emerging use of immune checkpoint blockade in the adjuvant setting for solid tumors: a review.
Moujaess E; Haddad FG; Eid R; Kourie HR
Immunotherapy; 2019 Nov; 11(16):1409-1422. PubMed ID: 31621445
[TBL] [Abstract][Full Text] [Related]
14. Recent success and limitations of immune checkpoint inhibitors for cancer: a lesson from melanoma.
Ottaviano M; De Placido S; Ascierto PA
Virchows Arch; 2019 Apr; 474(4):421-432. PubMed ID: 30747264
[TBL] [Abstract][Full Text] [Related]
15. Non-Melanoma Skin Cancers: Biological and Clinical Features.
Cives M; Mannavola F; Lospalluti L; Sergi MC; Cazzato G; Filoni E; Cavallo F; Giudice G; Stucci LS; Porta C; Tucci M
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32751327
[TBL] [Abstract][Full Text] [Related]
16. A Retrospective Study of Ipilimumab Plus Nivolumab in Anti-PD-L1/PD-1 Refractory Merkel Cell Carcinoma.
Shalhout SZ; Emerick KS; Kaufman HL; Silk AW; Thakuria M; Miller DM
J Immunother; 2022 Sep; 45(7):299-302. PubMed ID: 35877101
[TBL] [Abstract][Full Text] [Related]
17. Real-world clinical outcomes with first-line avelumab in locally advanced/metastatic Merkel cell carcinoma in the USA: SPEAR-Merkel.
Cowey CL; Liu FX; Kim R; Boyd M; Fulcher N; Krulewicz S; Kasturi V; Bhanegaonkar A
Future Oncol; 2021 Jun; 17(18):2339-2350. PubMed ID: 33709776
[TBL] [Abstract][Full Text] [Related]
18. New perspectives in Merkel cell carcinoma.
Del Marmol V; Lebbé C
Curr Opin Oncol; 2019 Mar; 31(2):72-83. PubMed ID: 30694842
[TBL] [Abstract][Full Text] [Related]
19. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
20. Classic and new strategies for the treatment of advanced melanoma and non-melanoma skin cancer.
Rubatto M; Sciamarrelli N; Borriello S; Pala V; Mastorino L; Tonella L; Ribero S; Quaglino P
Front Med (Lausanne); 2022; 9():959289. PubMed ID: 36844955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
